TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06275958
Drug: Doublet Chemotherapy, Standard Dose (100%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
Study: NCT06275958
Drug: Doublet Chemotherapy, Dose-reduced (75%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
Study: NCT06275958
Drug: Monotherapy, Standard Dose (100%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
Study: NCT06275958
Drug: Monotherapy, Dose-reduced (75%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% of:~- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
Study: NCT04650893
Drug: Intravenous Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
Study: NCT04650893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control
Study: NCT05487391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06160167
Drug: IMiD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with MM treated with IMiDs
Study: NCT06160167
Drug: No IMiD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with MM not treated with IMiDs
Study: NCT06160167
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with MM treated with systemic therapy
Study: NCT05670184
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
Study: NCT05183984
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period
Study: NCT05205837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug - Placebo Intramuscular injektion - placebo
Study: NCT05462496
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3
Study: NCT04571580
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intracoronary infusion with normal saline
Study: NCT06556173
Drug: VTX3232
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose A
Study: NCT06490263
Drug: Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.
Study: NCT06490263
Drug: Mulberry Twig Alkaloids Tablets with single dose in healthy subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parts Two: Administered by swallowing after meals with four distinct dosage groups.
Study: NCT06490263
Drug: Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
Study: NCT06434493
Drug: Concurrent oral capecitabine chemotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days
Study: NCT06076213
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT06434636
Drug: Transamine 10% IV/IM Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg tranexamic acid (Transamine 10% IV/IM Injectable Solution) will be placed into 100 cc physiological saline through the appropriate vascular access and injected within 15 minutes.
Study: NCT06434636
Drug: %0.9 Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 cc %0.9 Normal Saline will be injected through the appropriate vascular access within 15 minutes
Study: NCT05158699
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac topical eye drops (Yellox)
Study: NCT05158699
Drug: Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
Normalized name: ketorolac-phenylephrine ophthalmic 0.3%-1% intraocular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
Study: NCT04946370
Drug: Androgen receptor pathway inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.
Study: NCT06554639
Drug: MK-5684
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via oral tablet per dosing regimen.
Study: NCT06643078
Drug: HL231 Solution for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg, treatment period; 52-weeks fixed dose.
Study: NCT06643078
Drug: Ultibro 110μg/50 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultibro capsule for inhalation once per day via Breezhaler, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, treatment period; 52-weeks fixed dose.
Study: NCT06637761
Drug: NeoMTA2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-active bio-ceramic mineral trioxide aggregate
Study: NCT06640777
Drug: Supportive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
Study: NCT06639295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous (SC) injection.
Study: NCT06641960
Drug: Probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction with probiotic lozenges.
Study: NCT06639282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
Study: NCT06640309
Drug: Nicotinamide Tablet
Normalized name: Nicotinamide Tablet
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide is anti-inflammatory and antioxidant.
Study: NCT05837897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab placebo-matching IV infusion
Study: NCT05152485
Drug: BIIB104 Reference Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05152485
Drug: BIIB104 Test Formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06277284
Drug: MG-K10 humanized monoclonal antibody injection（Penicillin bottle）
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG-K10 humanized monoclonal antibody injection (single injection)
Study: NCT04794504
Drug: Botox 100 UNT Injection
Normalized name: Botox 100 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox will be injected intramuscularly into the masseter and temporalis muscles bilaterally to investigate if it can supplement postoperative analgesia in orthognathic surgery patients
Study: NCT04139304
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04139304
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04139304
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05941585
Drug: HomoharringtonineD1-D7(2mg/m2/day)
Normalized name: STEARIC ACID D7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoharringtonine intravenous infusion on D1-D7,2mg/m2/day in a 4-week treatment cycle.
Study: NCT05102448
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Methotrexate (15mg each week) for 12 months~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria.
Study: NCT06014801
Drug: Dialysate fluid, Filtration replacement fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of continuous hemodialysis and/or hemofiltration
Study: NCT05885594
Drug: [18F]NOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.
Study: NCT06454110
Drug: NM8074
Approvals — FDA: no, EMA: no, PMDA: no
Description: NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
Study: NCT05397665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral suspension
Study: NCT05087342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be given to the control group per the schedule outlined in the armed description.
Study: NCT06403735
Drug: QLC1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
Study: NCT05589597
Drug: EO4010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential assignment
Study: NCT05547542
Drug: [11C]-LY2795050
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection
Study: NCT06675734
Drug: diclofenac sodium solution
Normalized name: Diclofenac Sodium Solution
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The experimental group consisted of patients in whom diclofenac sodium was administered IM and the control group consisted of patients in whom diclofenac sodium was administered orally only.
Study: NCT06690840
Drug: Atezolizumab in combination with Cyclophosphamide and Vinorelbine
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles
Study: NCT05147493
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
Study: NCT06174220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo 1g po daily
Study: NCT06570369
Drug: SP-624
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, once daily for 2 weeks
Study: NCT06570369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, once daily for 2 weeks
Study: NCT06365502
Drug: Guideline-directed medical treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: All individuals will receive guideline-directed medical treatment.
Study: NCT05708690
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
Study: NCT06570538
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 2.0 μg/kg, 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
Study: NCT05603182
Drug: PRA052
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRA052
Study: NCT05704088
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: randomized control trial, control group will receive placebo tablets
Study: NCT04714177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
Study: NCT04198649
Drug: Non-surgical periodontal treatment and azithromycin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions
Study: NCT06564714
Drug: Usual routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen is initiated only when acute spasticity is deemed problematic.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response.
Study: NCT05341843
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
Study: NCT05412979
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine
Study: NCT04522739
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.
Study: NCT04522739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo to match spironolactone will be taken orally once per day for 12 months.
Study: NCT06639984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate \&amp; Lyle, Staley, London, UK)
Study: NCT06638034
Drug: 68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
Study: NCT04904913
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI362 administered subcutaneously (SC) once a week.
Study: NCT04588792
Drug: Nebulized Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered by nebulization through the ventilator circuit
Study: NCT05838287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Pioglitazone
Study: NCT05906199
Drug: Renexin CR 200/160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of Renexin CR 200/160mg, QD
Study: NCT06641661
Drug: Hybutimibe 10mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybutimibe was added to the conventional treatment
Study: NCT06559241
Drug: Best medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.
Study: NCT06277219
Drug: LAT010
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAT010 monotherapy
Study: NCT06277219
Drug: LAT010 + ICI
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAT010 combination with PD-1 inhibitor
Study: NCT06570980
Drug: sulfonylurease with metformin, DPP4 inhibitors with Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic agents
Study: NCT06312254
Drug: Topical Phenytoin 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug is used to pharmacologically modulate peripheral sensory afferents
Study: NCT05039489
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
Study: NCT05972785
Drug: Calcium channel blocker
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with ATC code C08 will be categorised as calcium channel blockers.
Study: NCT05972785
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with ATC code C07 will be categorised as beta-blockers.
Study: NCT05972785
Drug: Diuretic
Normalized name: Diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with ATC code C03 will be categorised as diuretics.
Study: NCT05972785
Drug: None AHT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: None AHT
Study: NCT06114628
Drug: GSK3036656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily dosage of 20mg.
Study: NCT04816721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension to match EDP-938
Study: NCT06643260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive control
Study: NCT06569355
Drug: VCT220
Approvals — FDA: no, EMA: no, PMDA: no
Description: A small molecule GLP-1R agonist tablet, orally administration, once daily
Study: NCT06569355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05618925
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate and has the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1.
Study: NCT06673654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
Study: NCT06433921
Drug: Salbutamol HFA-152a
Normalized name: HYDROFLUOROCARBON 152A
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
Study: NCT06433921
Drug: Salbutamol HFA-134a
Normalized name: HYDROFLUOROCARBON 134A
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
Study: NCT06433921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
Study: NCT06186531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
Study: NCT05513573
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg, D1，Q3W
Study: NCT05513573
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
Study: NCT05708508
Drug: ROVALCYTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immuno-guided strategy arm
Study: NCT05179577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT06368960
Drug: BM201 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM201 injection：Dose escalation：24mg to 240mg
Study: NCT06161220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching the carbidopa capsules
Study: NCT06253650
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of: T-DXd at the dose of 6.4 mg/kg intravenous every 3 weeks plus capecitabine 1000 mg/sqm BID orally on days 1-14 every 3 weeks or 5-fluorouracil 600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks as per Investigator's choice
Study: NCT04984200
Drug: Mydriatic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Study: NCT05470283
Drug: OBX-115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05470283
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV